# US 2013/0280286 A1 · Medicament for lct poisoning

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280286 A1
- Document ID: US20130280286A1
- Status: Published application
- Kind: A1
- Application number: 13/483,701
- Filed: 2012-05-30
- Published: 2013-10-24
- Earliest claimed: 2006-08-02
- Assignees: Johannes Gutenberg-Universitaet Mainz
- Inventors: Christoph VON EICHEL-STREIBER; Jessica REINEKE; Stefan TENZER; Hansjörg SCHILD; Maja RUPNIK
- Web page: https://patentgrep.com/patent/US20130280286A1

## CPC

- C07K 14/33: from Clostridium (G)
- A61K 31/04: Nitro compounds
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/6615: Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- A61K 31/7024: Esters of saccharides
- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/1282: Clostridium (G)
- C07K 16/40: against enzymes
- C12N 9/99: Enzyme inactivation by chemical treatment
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins).

## Claims

### Claim 1

Method for preventing or relieving poisoning by LCT (=large clostridial cytotoxins), comprising:
administering to a host in need thereof at least one inhibitor or activator of an autocatalytic protease activity of said LCT in an amount effective to prevent or relieve poisoning by LCT by stopping a cytotoxically effective fragment of said LCT which has glycosyl transferase function to arrive in a host's cell cytosol.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said at least one inhibitor is an inhibitor of the autocataytic protease activity of one or more of the following proteases: protease of Clostridium difficile toxin A (TcdA), protease of Clostridium difficile toxin B (TcdB), protease of Clostridium sordellii lethal toxin (TcsL) or protease of Clostridium novyi α-toxin (Tcnα).

### Claim 3 (depends on 2)

The method according to claim 2, wherein the inhibitor is 1,2-epoxy-3-(p-nitrophenoxy)-propane (EPNP).

### Claim 4 (depends on 1)

The method according to claim 1, wherein the activator is an inositol phosphate, preferably inositol hexaphosphate (IP6).

### Claim 5 (depends on 2)

The method according to claim 2, wherein the inhibitor is a competitively inhibiting structural analogue of inositol phosphate.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the activator is a substance which analogous to IP6 promotes (autocatalytic) protease activity of LCTs.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance that reduces an inositol phosphate concentration in gut lumen of mammals including humans.

### Claim 8 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance that reduces an inositol phosphate concentration in mammalian cells.

### Claim 9 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody and interacts with an active centre of the protease in TcdB.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the inhibitor interacts with SEQ ID NO: 1.

### Claim 11 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody, which interacts with the DXG motif at amino acid position AS 1665 of the TcdB protein according to SEQ ID NO: 1 and table 3 line 1.

### Claim 12 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with SEQ ID NO: 2.

### Claim 13 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with a DXG motif at amino acid position AS 1662 of SEQ ID NO: 2 and table 3 line 2.

### Claim 14 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with SEQ ID NO: 3.

### Claim 15 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with a DXG motif at amino acid position AS 1666 of a TcsL protein according to SEQ ID NO: 3 and table 3 line 3.

### Claim 16 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly—an antibody which interacts with SEQ ID NO: 4.

### Claim 17 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody and interacts with a TcdB protein region of AS 1400 to AS 2300 according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) or with protein regions of TcdA or TcsL or Tcnαhomologous thereto.

### Claim 18 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody and interacts with a TcdB protein region of AS 1517 to AS 2142 according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) or with protein regions of TcdA or TcsL or Tcnαhomologous thereto.

### Claim 19 (depends on 2)

The method according to claim 2, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody and interacts with a TcdB protein region of AS 1517 to AS 1593 or of AS 1918 to AS 2142 according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) or with protein regions of TcdA or TcsL or Tcnα homologous thereto.

### Claim 20

Method for preventing or relieving poisoning by LCTcomprising:
administering a medicament that
(1.) is suited for administration as a vaccine and
(2.) as an antigen active ingredient
(a) contains a TcdB protein fragment which comprises at least a DXG motif at position 1665, preferably an amino acid sequence of amino acid positions AS 1653 to AS 1678 [SEQ ID NO 1],
and/or (b) contains a TcdA protein fragment which comprises at least a DXG motif at position 1662, preferably an amino acid sequence of amino acid positions
AS 1651 to AS 1675 [SEQ ID NO: 2],
and/or (c) contains a TcsL protein fragment which comprises at least a DXG motif at position 1666, preferably an amino acid sequence of amino acid positions AS 1654 to AS 1679 [SEQ ID NO: 3],
and/or (d) contains a Tcnα protein fragment which comprises at least an amino acid sequence of AS 1641 to AS 1665 [SEQ ID NO: 4].

### Claim 21 (depends on 1)

The method according to claim 1, wherein said at least one activator of a protease activity is an activator of the autocataytic protease activity of one or more of the following proteases: protease of Clostridium difficile toxin A (TcdA), protease of Clostridium difficile toxin B (TcdB), protease of Clostridium sordellii lethal toxin (TcsL) or protease of Clostridium novyi α-toxin (Tcnα).

### Claim 22 (depends on 21)

The method according to claim 21, wherein the activator interacts with one or more of the protease of Clostridium difficile toxin A (TcdA), Clostridium difficile toxin B (TcdB), Clostridium sordellii lethal toxin (TcsL) or Clostridium novyi α-toxin (Tcnα), initiates said protease activity and wherein a cytotoxically effective fragment of said Clostridium difficile toxin A (TcdA), Clostridium difficile toxin B (TcdB), Clostridium sordellii lethal toxin (TcsL) or Clostridium novyi α-toxin (Tcnα), respectively, is autocatalytically split off via said protease activity outside a host cell.

### Claim 23 (depends on 1)

The method of claim 1, wherein said activator activates said protease activity before the LCT has bound to the host cell and splits off the cytotoxically effective fragment of said LCT outside the host cell.

### Claim 24 (depends on 1)

The method of claim 1, wherein said inhibitor inhibits said protease activity of said LCT by interacting with the LCT and preventing an autocataytic splitting off or autocleavage of the cytotoxically effective fragment of said LCT via said protease activity.

### Claim 25

Method for stopping protease cleavage of a LCT, comprising providing an inhibitor of the autocataytic protease activity of one or more of the following proteases: protease of Clostridium difficile toxin A (TcdA); protease of Clostridium difficile toxin B (TcdB); protease of Clostridium sordellii lethal toxin (TcsL) or protease of Clostridium novyi α-toxin (Tcnα), wherein the inhibitor interacts with the protease of Clostridium difficile toxin A (TcdA); Clostridium difficile toxin B (TcdB); Clostridium sordellii lethal toxin (TcsL) or Clostridium novyi α-toxin (Tcnα) respectively, and inhibits said protease activity to autocatalytically split off the cytotoxically effective fragment of said Clostridium difficile toxin A (TcdA); Clostridium difficile toxin B (TcdB); Clostridium sordellii lethal toxin (TcsL) or Clostridium novyi α-toxin (Tcnα), respectively, outside a host cell.
